| IBO |
Impact BioMedical Inc. |
80%
|
Reciprocal relationship from IBO graph: Reciprocal relationship from PRPH graph: Reciprocal relationship from IBO graph: Reciprocal relationship from PRPH graph: Reciprocal relationship from IBO grap… |
| DGX |
Quest Diagnostics Incorporated |
72%
|
Reciprocal relationship from DGX graph: Reciprocal relationship from PRPH graph: avorable interpretation of EKRA for laboratory compensation structures, we cannot be assured that courts in our jurisd… |
| DGX |
Quest Diagnostics Incorporated |
72%
|
avorable interpretation of EKRA for laboratory compensation structures, we cannot be assured that courts in our jurisdiction will reach the same conclusion or that the decision will not be overturned… |
| FISI |
Financial Institutions, Inc. |
72%
|
operating performance without regard to certain expenses. EBITDA and Adjusted EBITDA are not presentations made in accordance with GAAP and the Company’s computation of EBITDA and Adjusted EBITDA may… |
| FISI |
Financial Institutions, Inc. |
72%
|
Reciprocal relationship from FISI graph: Reciprocal relationship from PRPH graph: Reciprocal relationship from FISI graph: Reciprocal relationship from PRPH graph: Reciprocal relationship from FISI g… |
| IDXG |
Interpace Biosciences, Inc. |
72%
|
Reciprocal relationship from IDXG graph: Reciprocal relationship from PRPH graph: COVID-19 and other RPP Molecular tests. Additionally, we compete against regional clinical laboratories providing dia… |
| IDXG |
Interpace Biosciences, Inc. |
72%
|
COVID-19 and other RPP Molecular tests. Additionally, we compete against regional clinical laboratories providing diagnostic services, including Interpace Biosciences, Inc. The number of companies en… |
| GLOBAL-BIOLIFE-INC |
GLOBAL-BIOLIFE-INC |
62%
|
s that were obtained from 130 countries and are equivalent to roughly 150 million ancestry single nucleotide polymorphisms based tests. DNA Complete is not rated by the Better Business Bureau and Neb… |
| KEYSTONE-CAPITAL-PARTNERS-LLC |
KEYSTONE-CAPITAL-PARTNERS-LLC |
62%
|
. This shall be multiplied by the purchase price unless amounts collected prior to the date in which the repurchase price is paid. During the three and nine months ended September 30, 2025 , the Comp… |
| LIBERTAS-FUNDING-LLC |
LIBERTAS-FUNDING-LLC |
62%
|
. On April 9, 2025, the Company entered into another agreement of sale of future receipts (the “Third Amended Slate Financing Agreement”) with Slate pursuant to which Slate restructured the existing … |
| NEBULA-GENOMICS-INC |
NEBULA-GENOMICS-INC |
62%
|
ising in the ordinary course of our business. One of our subsidiaries, Nebula Genomics, Inc., is currently involved in a class action lawsuit that, based on our review of the facts and circumstances,… |
| PHARMALOZ-MANUFACTURING-INC |
PHARMALOZ-MANUFACTURING-INC |
62%
|
. This shall be multiplied by the purchase price unless amounts collected prior to the date in which the repurchase price is paid. During the three and nine months ended September 30, 2025 , the Comp… |
| PHARMALOZ-REAL-ESTATE-HOLDINGS-INC |
PHARMALOZ-REAL-ESTATE-HOLDINGS-INC |
62%
|
. This shall be multiplied by the purchase price unless amounts collected prior to the date in which the repurchase price is paid. During the three and nine months ended September 30, 2025 , the Comp… |
| PROPHASE-DIAGNOSTICS-INC |
PROPHASE-DIAGNOSTICS-INC |
62%
|
commercialize Equivir as a dietary supplement, leveraging our distribution in over 40,000 FDM retail stores and online direct to consumers. In March 2023, we commenced patient enrollment in a randomi… |
| PROPHASE-DIAGNOSTICS-NJ-INC |
PROPHASE-DIAGNOSTICS-NJ-INC |
62%
|
commercialize Equivir as a dietary supplement, leveraging our distribution in over 40,000 FDM retail stores and online direct to consumers. In March 2023, we commenced patient enrollment in a randomi… |
| PROPHASE-DIAGNOSTICS-NY-INC |
PROPHASE-DIAGNOSTICS-NY-INC |
62%
|
commercialize Equivir as a dietary supplement, leveraging our distribution in over 40,000 FDM retail stores and online direct to consumers. In March 2023, we commenced patient enrollment in a randomi… |
| STAGE-ADVANCE-LLC |
STAGE-ADVANCE-LLC |
62%
|
alue of the August Warrants were valued at $ 120,000 using the Black-Scholes option pricing model with the following assumptions: no dividend yield, expected volatility of 98.3 % , risk free interest… |
| STELLA-DIAGNOSTICS-INC |
STELLA-DIAGNOSTICS-INC |
62%
|
ue when performance obligations with our customers have been satisfied. At contract inception, we evaluate the contract to determine if revenue should be recognized using the following five steps: (1… |
| STELLA-DX-LLC |
STELLA-DX-LLC |
62%
|
ue when performance obligations with our customers have been satisfied. At contract inception, we evaluate the contract to determine if revenue should be recognized using the following five steps: (1… |
| TERRAPIN-BUSINESS-FUNDING-LLC |
TERRAPIN-BUSINESS-FUNDING-LLC |
62%
|
o note agreements (collectively the "Third August 2025 Notes") with same individual investor for an aggregate cash proceeds of $ 400,000 , which is net of original issue discount and issuance cost of… |
| THINKEQUITY-LLC |
THINKEQUITY-LLC |
62%
|
re $5.3 million, comprised of $2.1 million for diagnostic services and $3.1 million for consumer products. We realized a gross margin profit o f $1.1 million for the nine months ended September 30, 2… |
| WESTPARK-CAPITAL-INC |
WESTPARK-CAPITAL-INC |
62%
|
re $5.3 million, comprised of $2.1 million for diagnostic services and $3.1 million for consumer products. We realized a gross margin profit o f $1.1 million for the nine months ended September 30, 2… |
